- Home
- SNTI vs MGN Comparison
SNTI vs MGN Comparison
Compare SNTI & MGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- MGN
- Stock Information
- Founded
- SNTI 2016
- MGN 2020
- Country
- SNTI United States
- MGN Malaysia
- Employees
- SNTI N/A
- MGN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- MGN
- Sector
- SNTI Health Care
- MGN
- Exchange
- SNTI Nasdaq
- MGN Nasdaq
- Market Cap
- SNTI 53.6M
- MGN 43.0M
- IPO Year
- SNTI N/A
- MGN 2025
- Fundamental
- Price
- SNTI $2.15
- MGN $1.66
- Analyst Decision
- SNTI Strong Buy
- MGN
- Analyst Count
- SNTI 3
- MGN 0
- Target Price
- SNTI $9.67
- MGN N/A
- AVG Volume (30 Days)
- SNTI 327.7K
- MGN 713.5K
- Earning Date
- SNTI 11-13-2025
- MGN 11-11-2025
- Dividend Yield
- SNTI N/A
- MGN N/A
- EPS Growth
- SNTI N/A
- MGN N/A
- EPS
- SNTI N/A
- MGN 0.07
- Revenue
- SNTI N/A
- MGN $13,484,571.00
- Revenue This Year
- SNTI N/A
- MGN N/A
- Revenue Next Year
- SNTI $150.00
- MGN N/A
- P/E Ratio
- SNTI N/A
- MGN $24.67
- Revenue Growth
- SNTI N/A
- MGN N/A
- 52 Week Low
- SNTI $1.26
- MGN $1.60
- 52 Week High
- SNTI $16.94
- MGN $8.63
- Technical
- Relative Strength Index (RSI)
- SNTI 62.17
- MGN N/A
- Support Level
- SNTI $1.92
- MGN N/A
- Resistance Level
- SNTI $2.29
- MGN N/A
- Average True Range (ATR)
- SNTI 0.25
- MGN 0.00
- MACD
- SNTI 0.01
- MGN 0.00
- Stochastic Oscillator
- SNTI 55.06
- MGN 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.